Carl Zeiss Meditec AG (CZMWY)
99.09
-3.18
(-3.11%)
USD |
OTCM |
May 23, 15:54
Carl Zeiss Meditec Enterprise Value: 9.125B for May 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 22, 2024 | 9.125B |
| May 21, 2024 | 9.037B |
| May 20, 2024 | 9.204B |
| May 17, 2024 | 9.260B |
| May 16, 2024 | 9.388B |
| May 15, 2024 | 9.279B |
| May 14, 2024 | 9.327B |
| May 13, 2024 | 8.962B |
| May 10, 2024 | 9.107B |
| May 09, 2024 | 9.026B |
| May 08, 2024 | 8.991B |
| May 07, 2024 | 9.530B |
| May 06, 2024 | 9.629B |
| May 03, 2024 | 9.393B |
| May 02, 2024 | 9.324B |
| May 01, 2024 | 9.550B |
| April 30, 2024 | 9.391B |
| April 29, 2024 | 9.617B |
| April 26, 2024 | 9.578B |
| April 25, 2024 | 9.494B |
| April 24, 2024 | 9.606B |
| April 23, 2024 | 9.788B |
| April 22, 2024 | 9.388B |
| April 19, 2024 | 9.255B |
| April 18, 2024 | 9.218B |
| Date | Value |
|---|---|
| April 17, 2024 | 9.208B |
| April 16, 2024 | 9.666B |
| April 15, 2024 | 9.700B |
| April 12, 2024 | 9.675B |
| April 11, 2024 | 9.957B |
| April 10, 2024 | 10.08B |
| April 09, 2024 | 10.34B |
| April 08, 2024 | 10.35B |
| April 05, 2024 | 10.29B |
| April 04, 2024 | 10.52B |
| April 03, 2024 | 10.75B |
| April 02, 2024 | 11.05B |
| April 01, 2024 | 11.52B |
| March 31, 2024 | 11.17B |
| March 28, 2024 | 11.19B |
| March 27, 2024 | 11.58B |
| March 26, 2024 | 11.50B |
| March 25, 2024 | 11.43B |
| March 22, 2024 | 11.47B |
| March 21, 2024 | 11.22B |
| March 20, 2024 | 11.47B |
| March 19, 2024 | 11.70B |
| March 18, 2024 | 11.67B |
| March 15, 2024 | 11.75B |
| March 14, 2024 | 11.93B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.426B
Minimum
Mar 18 2020
21.06B
Maximum
Sep 15 2021
11.90B
Average
11.16B
Median
Jan 03 2023
Enterprise Value Benchmarks
| Affimed NV | 5.943M |
| InflaRx NV | 5.359M |
| MorphoSys AG | 2.695B |
| BioNTech SE | 7.990B |
| Immatics NV | 456.56M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 50.48M |
| Revenue (Quarterly) | 512.82M |
| Total Expenses (Quarterly) | 442.53M |
| EPS Diluted (Quarterly) | 0.5648 |
| Gross Profit Margin (Quarterly) | 53.49% |
| Profit Margin (Quarterly) | 9.84% |
| Earnings Yield | 3.21% |
| Operating Earnings Yield | 3.84% |
| Normalized Earnings Yield | 3.215 |